摘要
背景:Duchenne型肌营养不良症(DMD)是由DMD基因突变引起的肌营养不良症导致的X连锁神经肌肉疾病。由于肌营养不良蛋白对维持肌膜的完整性至关重要,蛋白的缺失导致肌肉损伤和DMD疾病的表现。目前,只有对症治疗是无法治愈的。 目的:DMD疗法的最新进展不能为DMD提供永久治疗。 CRISPR / Cas技术作为DMD基因治疗的有吸引力的平台,依赖于和独立于特定的突变。 方法:CRISPR / Cas技术可通过调节疾病修饰因子而独立于患者突变而使用。关于DMD重复突变,可以使用单一sgRNA方法恢复全长肌营养不良蛋白。对于DMD缺失和点突变,通过去除或重新构建外显子以产生较短形式的肌养蛋白,可以恢复开放阅读框(ORF)。全长野生型肌营养不良蛋白还可以使用同源重组(HR)来恢复。用于这些策略的CRISPR / Cas组分是使用腺伴随病毒(AAV)载体在体内递送的。 结果:一种称为utrophin的肌养蛋白同系物的上调可补偿肌营养不良蛋白的缺乏,并已在患者细胞中成功地证实。在患有重复突变的患者细胞中恢复全长肌养蛋白。使用CRISPR策略在体外和体内回收短形式和全长肌营养不良蛋白。 结论:恢复野生型和短肌型肌营养不良蛋白突显了CRISPR技术对DMD的治疗潜力
关键词: 杜氏肌营养不良,CRISPR,肌萎缩蛋白,基因治疗,临床试验,腺相关病毒。
Current Gene Therapy
Title:Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy
Volume: 17 Issue: 4
关键词: 杜氏肌营养不良,CRISPR,肌萎缩蛋白,基因治疗,临床试验,腺相关病毒。
摘要: Background: Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease caused by the lack of dystrophin due to mutations in the DMD gene. Since dystrophin is essential in maintaining the integrity of the sarcolemmal membrane, the absence of the protein leads to muscle damage and DMD disease manifestation. Currently, there is no cure with only symptomatic management available.
Objective: The most recent advancements in DMD therapies do not provide a permanent treatment for DMD. CRISPR/Cas technology poses as an attractive platform for DMD gene therapy both dependent and independent of the specific mutation.
Method: CRISPR/Cas technology can be utilized independent of the patient mutation by modulating disease modifiers. Regarding DMD duplication mutations, full length dystrophin can be restored using a single sgRNA approach. For DMD deletion and point mutations, the open reading frame (ORF) can be restored by removing or reframing exon(s) to produce a shorter form of dystrophin. The full-length wildtype dystrophin can also be restored using homologous recombination (HR). The CRISPR/Cas components for these strategies were delivered in vivo using the adeno-associated virus (AAV) vector.
Results: The upregulation of a dystrophin homologue called utrophin can compensate for the lack of dystrophin protein, and has been successfully demonstrated in patient cells. Full-length dystrophin was restored in patient cells carrying duplication mutations. The shorter form and full-length dystrophin was recovered using CRISPR strategies in vitro and in vivo.
Conclusions: Restoration of the wild type and shorter form of dystrophin highlights the therapeutic potential of CRISPR technology for DMD.
Export Options
About this article
Cite this article as:
Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy, Current Gene Therapy 2017; 17 (4) . https://dx.doi.org/10.2174/1566523217666171121165046
DOI https://dx.doi.org/10.2174/1566523217666171121165046 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements